// App-Quantinova.ai

1001 : Phase III trial of etirinotecan pegol (EP) versus Treatment of Physicians Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study.

Researchers

Presenter

  • Edith A. Perez

Principal Investigators

  • Ahmad Awada

  • Seock-Ah Im

  • Carol Zhao

  • Ute Hoch

  • Alison L. Hannah

  • Javier Cortes

  • Joyce O'Shaughnessy

  • Hope S. Rugo

  • Chris Twelves

Medical Centers

  • Jules Bordet Institute, Bruxelles, Belgium

  • Seoul National University College of Medicine, Seoul, South KoreaVall dHebron University Hospital, Barcelona, SpainConsultant, Sebastopol, CA

  • Baylor Sammons Cancer Ctr US Onc, Dallas, TX

  • Mayo Clinic, Jacksonville, FL

  • University of California, San Francisco, San Francisco, CA

  • Nektar Therapeutics, San Francisco, CA

  • LIMM, Leeds, United Kingdom

Locations

  • United States

  • United Kingdom

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Brain metastasis

  • Secondary liver cancer

  • Breast cancer

  • Neutropenia

  • Peripheral neuropathy

  • Dyspnea

  • Solid malignancies

  • Anemia

Biomarkers

  • Circulating tumor cells

  • DNA topoisomerase 2-alpha

  • erb-b2 receptor tyrosine kinase 2

  • Topoisomerase-1

Drug/Treatment

  • etirinotecan pegol

  • Capecitabine

  • Gemcitabine

  • Ixabepilone

  • Vinorelbine

  • Eribulin

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01492101

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved